Classification of the Molecular Defects Associated with Pathogenic Variants of the SLC6A8 Creatine Transporter
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
More than 80 loss-of-function (LOF) mutations in the SLC6A8 creatine transporter (hCRT1) are responsible for cerebral creatine deficiency syndrome (CCDS), which gives rise to a spectrum of neurological defects, including intellectual disability, epilepsy, and autism spectrum disorder. To gain insight into the nature of the molecular defects caused by these mutations, we quantitatively profiled the cellular processing, trafficking, expression, and function of eight pathogenic CCDS variants in relation to the wild type (WT) and one neutral isoform. All eight CCDS variants exhibit measurable proteostatic deficiencies that likely contribute to the observed LOF. However, the magnitudes of their specific effects on the expression and trafficking of hCRT1 vary considerably, and we find that the LOF associated with two of these variants primarily arises from the disruption of the substrate-binding pocket. In conjunction with an analysis of structural models of the transporter, we use these data to suggest mechanistic classifications for these variants. To evaluate potential avenues for therapeutic intervention, we assessed the sensitivity of these variants to temperature and measured their response to the proteostasis regulator 4-phenylbutyrate (4-PBA). Only one of the tested variants (G132V) is sensitive to temperature, though its response to 4-PBA is negligible. Nevertheless, 4-PBA significantly enhances the activity of WT hCRT1 in HEK293T cells, which suggests it may be worth evaluating as a therapeutic for female intellectual disability patients carrying a single CCDS mutation. Together, these findings reveal that pathogenic SLC6A8 mutations cause a spectrum of molecular defects that should be taken into consideration in future efforts to develop CCDS therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low brain creatine content has been associated with muscle myopathies (e.g., weakness), voluntary or involuntary movement disorders that can affect muscle function and coordination, speech development, epilepsy, cognitive and motor development delays, and/or autism [53,61,203,204,206,207,208,209,210].”
From Creatine in health and disease (2021) · cites this paper as [210]
In the citing paper
“For this reason, high-dose, long-term creatine supplementation (e.g., 0.3–0.8 g/kg/day) throughout the lifespan is a nutritional strategy of increasing brain creatine content in these populations [53,61,203,204,206,207,208,209,210,211,212,213,214].”
From Creatine in health and disease (2021) · cites this paper as [210]
Citations
Cites
Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters
Yamashita, A., Singh, S. K., Kawate, T., Jin, Y., & Gouaux, E. (2005) · Nature · doi:10.1038/nature03978 · Cited by 1,661
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,234
High-Resolution Comparative Modeling with RosettaCM
Song, Y., DiMaio, F., Wang, R. Y.-R., Kim, D., Miles, C., Brunette, T., Thompson, J., & Baker, D. (2013) · Structure · doi:10.1016/j.str.2013.08.005 · Cited by 1,115
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794
SNPs, protein structure, and disease
Wang, Z., & Moult, J. (2001) · Human Mutation · doi:10.1002/humu.22 · Cited by 731
X-ray structures and mechanism of the human serotonin transporter
Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 668
The epidemiology of mental retardation: Challenges and opportunities in the new millennium
Leonard, H., & Wen, X. (2002) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10031 · Cited by 620
Fan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614
Veit, G., Avramescu, R. G., Chiang, A. N., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0935 · Cited by 580
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522
Ropers, H.-H., & Hamel, B. C. J. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1501 · Cited by 501
The prevalence of mental retardation: a critical review of recent literature
Roeleveld, N., & Zielhuis, G. A. (1997) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1997.tb07395.x · Cited by 450
Chen, N.-H., Reith, M. E. A., & Quick, M. W. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1064-5 · Cited by 409
Kerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., Wilschanski, M., Elborn, J. S., Melotti, P., Bronsveld, I., Fajac, I., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70100-6 · Cited by 346
Guimbal, C., & Kilimann, M. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52891-x · Cited by 298
X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes
Hu, H., Haas, S. A., Chelly, J., Van Esch, H., Raynaud, M., de Brouwer, A. P. M., Weinert, S., Froyen, G., Frints, S. G. M., Laumonnier, F., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2014.193 · Cited by 298
Pharmacological chaperones: potential treatment for conformational diseases
Bernier, V., Lagacé, M., Bichet, D. G., & Bouvier, M. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.05.003 · Cited by 283
Disease-Related Misassembly of Membrane Proteins
Sanders, C. R., & Myers, J. K. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140348 · Cited by 254
Marinko, J. T., Huang, H., Penn, W. D., Capra, J. A., Schlebach, J. P., & Sanders, C. R. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00532 · Cited by 252
Self-citationHigh Prevalence of SLC6A8 Deficiency in X-Linked Mental Retardation
Rosenberg, E. H., Almeida, L. S., Kleefstra, T., deGrauw, R. S., Yntema, H. G., Bahi, N., Moraine, C., Ropers, H.-H., Fryns, J.-P., deGrauw, T. J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/422102 · Cited by 213
Sorkina, T., Miranda, M., Dionne, K. R., Hoover, B. R., Zahniser, N. R., & Sorkin, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1301-06.2006 · Cited by 190
Cystic Fibrosis Transmembrane Regulator Correctors and Potentiators
Rowe, S. M., & Verkman, A. S. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009761 · Cited by 176
Clark, A. J., Rosenberg, E. H., Almeida, L. S., Wood, T. C., Jakobs, C., Stevenson, R. E., Schwartz, C. E., & Salomons, G. S. (2006) · Human Genetics · doi:10.1007/s00439-006-0162-9 · Cited by 144
A platform for functional assessment of large variant libraries in mammalian cells
Matreyek, K. A., Stephany, J. J., & Fowler, D. M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx183 · Cited by 138
The Cloning and Expression of a Human Creatine Transporter
Sora, I., Richman, J., Santoro, G. P., Wei, H.-B., Wang, Y., Vanderah, T. W., Horváth, R., Nguyen, M., Waite, S. L., Roeske, W. R., et al. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2475 · Cited by 132
Tobler, A. R., Notterpek, L., Naef, R., Taylor, V., Suter, U., & Shooter, E. M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-06-02027.1999 · Cited by 123
Creatine and Creatine Deficiency Syndromes: Biochemical and Clinical Aspects
Nasrallah, F., Feki, M., & Kaabachi, N. (2010) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2009.07.015 · Cited by 116
Disorders of creatine transport and metabolism
Longo, N., Ardon, O., Vanzo, R., Schwartz, E., & Pasquali, M. (2011) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30292 · Cited by 101
The clinical syndrome of creatine transporter deficiency
de Grauw, T. J., Cecil, K. M., Byars, A. W., Salomons, G. S., Ball, W. S., & Jakobs, C. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1022487218904 · Cited by 85
Expression of the Rat Brain Creatine Transporter in situ and in Transfected HeLa Cells
Saltarelli, M. D., Bauman, A. L., Moore, K. R., Bradley, C. C., & Blakely, R. D. (1996) · Developmental Neuroscience · doi:10.1159/000111450 · Cited by 75
Stimulation of the creatine transporter SLC6A8 by the protein kinases SGK1 and SGK3
Shojaeifard, M. B., Christie, D. L., & Lang, F. J. W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.164 · Cited by 64
Conformational Stability and Pathogenic Misfolding of the Integral Membrane Protein PMP22
Schlebach, J. P., Narayan, M., Alford, C. C., Mittendorf, K. F., Carter, B. D., Li, J., & Sanders, C. R. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b03743 · Cited by 63
Self-citationEl‐Kasaby, A., Kasture, A. S., Koban, F., Hoťka, M., Asjad, H. M. M., Kubista, H., Freissmuth, M., & Sučić, S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.015 · Cited by 58
Stimulation of the creatine transporter SLC6A8 by the protein kinase mTOR
Shojaeifard, M. B., Christie, D. L., & Lang, F. J. W. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.055 · Cited by 48
Defining the blanks – Pharmacochaperoning of SLC6 transporters and ABC transporters
Chiba, P., Freissmuth, M., & Stockner, T. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.009 · Cited by 47
Creatine and Creatine Kinase in Health and Disease – A Bright Future Ahead?
Wyss, M., Braissant, O., Pischel, I., Salomons, G. S., Schulze, A., Stockler, S., & Wallimann, T. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_16 · Cited by 46
Detection of variants in SLC6A8 and functional analysis of unclassified missense variants
Betsalel, O. T., Pop, A., Rosenberg, E. H., Fernandez-Ojeda, M. R., Jakobs, C., & Salomons, G. S. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.12.022 · Cited by 42
Rahbek‐Clemmensen, T., Bay, T., Eriksen, J., Gether, U., & Jørgensen, T. N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.495754 · Cited by 35
Cited by
Creatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
Metabolic Basis of Creatine in Health and Disease: A Bioinformatics-Assisted Review
Bonilla, D. A., Kreider, R. B., Stout, J. R., Forero, D. A., Kerksick, C. M., Roberts, M. D., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13041238 · Cited by 223
“Alterations in Cr concentrations due to CRT, AGAT, or GAMT deficiencies may produce functional changes in these tissues, leading to a wide range of diseases [14,22,49–51] that are grouped into the Cr deficiency syndrome [52].”
BackgroundThe Creatine Transporter Unfolded: A Knotty Premise in the Cerebral Creatine Deficiency Syndrome
Farr, C. V., El‐Kasaby, A., Freissmuth, M., & Sučić, S. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.588954 · Cited by 58
“Evidence for proteostatic deficiencies in several CTD mutants was also substantiated by data from the Schlabach group (Salazar et al., 2020).”
BackgroundBhat, S., El‐Kasaby, A., Freissmuth, M., & Sučić, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107785 · Cited by 55
De novo variants in ATP2B1 lead to neurodevelopmental delay
Rahimi, M. J., Urban, N. D., Wegler, M., Sticht, H., Schaefer, M., Popp, B., Gaunitz, F., Morleo, M., Nigro, V., Maitz, S. B., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.03.009 · Cited by 25
Metadata
- Authors
- Salazar, M. D., Zelt, N. B., Saldivar, R., Kuntz, C. P., Chen, S., Penn, W. D., Bonneau, R., Koehler Leman, J., & Schlebach, J. P.
- Affiliations
- Indiana University Bloomington (US)
- Simons Foundation (US)
- Center for Computational Biology, Flatiron Institute, Simons Foundation, New York, New York 10010, United States
- Corresponding author
- Schlebach, Jonathan P.
- ORCID
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-24
- Volume
- 59
- Issue
- 13
- Pages
- 1367-1377
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W3012606372
- Cited by
- 25
- References
- 38
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 8 · 2022: 1 · 2021: 3 · 2020: 4
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- SLC6A8, creatine transporter, cerebral creatine deficiency syndrome, loss-of-function mutations, protein trafficking, substrate binding pocket, proteostasis, 4-phenylbutyric acid, temperature sensitivity, intellectual disability, epilepsy, autism spectrum disorder, transporter structure
- MeSH terms
- Creatine, Humans, Nerve Tissue Proteins, Phenylbutyrates, Mutation, Missense, Brain Diseases, Metabolic, Inborn, Membrane Transport Proteins, X-Linked Intellectual Disability, Mental Retardation, X-Linked, Plasma Membrane Neurotransmitter Transport Proteins, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.